Présentation de l'entreprise
Imunon, Inc. operates as a clinical-stage biotechnology entity dedicated to the development of advanced immunotherapies and vaccines, with a primary focus on localized treatments for specific oncological indications. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to capitalize on high-growth opportunities in oncology research and therapeutic innovation. As of the latest reporting period, the entity maintains a market capitalization of $12.28M, operates with an annual revenue figure that is not disclosed in current filings, and employs a workforce count listed as N/A. These valuation metrics indicate that the company is a small-cap entity with a market capitalization under $50M, suggesting a position in the early-to-mid stage of development where capital efficiency and successful clinical trial execution are critical determinants of future market relevance rather than established revenue streams or large-scale production capabilities.
Santé financière
The company reported a net income of $-14,495,028 over the trailing twelve months, while EBITDA stood at $-14,358,786, reflecting significant operational losses typical for biotechnology firms in the clinical development phase. The substantial negative net income relative to the reported revenue figures—which are N/A—reveals a cost structure driven almost entirely by research and development expenditures and clinical trial costs rather than cost of goods sold or overhead inefficiencies. Free cash flow is recorded at $-8,529,147, indicating that the company is currently burning cash to fund its pipeline, which limits immediate financial flexibility and necessitates reliance on external capital sources such as equity issuances or strategic partnerships. The company holds $8.78M in cash and cash equivalents against a total debt load of $1.01M, providing a liquidity buffer that allows for continued operations despite the negative cash flow environment. However, the debt-to-equity ratio of 14.29 suggests a highly leveraged balance sheet relative to shareholders' equity, which is an unusual metric for a cash-burning biotech firm but must be interpreted in the context of its specific capital structure and potential off-balance-sheet obligations. Gross margin, operating margin, and profit margin are all reported at 0.0%, a standard characteristic for clinical-stage biotechs that have not yet achieved commercial product sales to generate gross profit. The current ratio of 2.32 indicates that the company possesses liquid assets more than twice the value of its short-term liabilities, suggesting adequate short-term liquidity to meet obligations as they come due. Furthermore, the Return on Equity of -256.4% and Return on Assets of -83.2% demonstrate that management is currently utilizing shareholder capital and assets to generate negative returns, a metric expected for pre-revenue companies but indicative of the high capital intensity required to advance their lead clinical program.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not applicable (N/A) due to the lack of net income, while the forward P/E is listed as -1.00, a metric that becomes mathematically negative or undefined when earnings are negative and implies that traditional earnings-based valuation models are not suitable for assessing the company's current worth. The price-to-book ratio stands at 1.30, indicating that the market values the company's equity at 30% above its book value, which reflects the potential intangible value of its intellectual property and clinical pipeline despite current losses. Price-to-sales and EV/EBITDA metrics are also provided as N/A or -0.31 respectively, suggesting that investors must rely on alternative valuation frameworks such as discounted cash flow models or peer group comparisons based on clinical milestones rather than traditional multiple expansion. The stock has traded between a 52-week high of $41.22 and a 52-week low of $2.52, illustrating extreme price volatility often associated with speculative biotechnology stocks that rely heavily on binary clinical trial outcomes. The beta value of 2.12 signifies that the stock's price volatility is more than twice that of the broader market, meaning the asset is expected to experience significantly larger price swings in both upward and downward directions compared to large-cap equities. These valuation characteristics collectively highlight the high-risk nature of the investment, where the market price is detached from current financial performance and instead priced on the probability of future commercial success for the lead clinical program IMNN-001.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a clinical-stage entity that has not yet reached a stage where historical growth rates can be meaningfully calculated from comparable periods. Since the company does not pay a dividend, the dividend yield and payout ratio are both N/A or 0.0%, indicating that all available capital is being reinvested directly into research and development activities rather than distributed to shareholders. The absence of dividend payments is consistent with the business model of a clinical-stage biotechnology company that prioritizes funding its pipeline, specifically the Phase II development of IMNN-001, over returning capital to investors. The overall growth and income profile is characterized by zero current profitability, no dividend income, and growth potential that is entirely contingent upon the successful advancement of its preclinical stage products and lead clinical program through regulatory approval and commercialization phases.